275 related articles for article (PubMed ID: 18018584)
21. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
22. [Granulomas induced by injections of leuprorelin acetate (Enantone®)].
Bruneu-Avierinos Y; Monestier S; Tasei AM; Gaudy-Marqueste C; Grob JJ; Richard MA
Ann Dermatol Venereol; 2011 Jan; 138(1):35-7. PubMed ID: 21276459
[TBL] [Abstract][Full Text] [Related]
23. [Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate].
Fukui S; Nakai Y; Matsumoto Y; Kagebayashi Y; Samma S
Hinyokika Kiyo; 2015 Feb; 61(2):55-9. PubMed ID: 25812594
[TBL] [Abstract][Full Text] [Related]
24. A case of foreign body granuloma induced by subcutaneous injection of leuprorelin acetate─clinical analysis for 335 cases in our hospital─.
Kawai M; Ikoma N; Yamada A; Ota T; Manabe Y; Kato M; Mabuchi T; Ozawa A; Higure T; Terachi T
Tokai J Exp Clin Med; 2014 Sep; 39(3):106-10. PubMed ID: 25248424
[TBL] [Abstract][Full Text] [Related]
25. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
26. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
27. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
28. Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
J Nippon Med Sch; 2007 Aug; 74(4):306-8. PubMed ID: 17878701
[TBL] [Abstract][Full Text] [Related]
29. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
30. [Characteristics, effects, side effects of the LH-RH agonist].
Miyanaga N; Akaza H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
[No Abstract] [Full Text] [Related]
31. Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
Ishizuka O; Nishizawa O; Nishizawa S; Satoh T; Wajiki M; Kiyokawa H; Inoue Y; Kobayashi S; Mizusawa H; Nakagawa T
Int J Clin Oncol; 2013 Jun; 18(3):524-30. PubMed ID: 22552359
[TBL] [Abstract][Full Text] [Related]
32. Effects of luteinizing hormone-releasing hormone (LH-RH) analogue on the function of the isolated rabbit corpus cavernosum.
Itoh Y; Ando M; Ohmura M; Kondo A; Miyake K; Saito M
Hinyokika Kiyo; 1996 Mar; 42(3):215-20. PubMed ID: 8619392
[TBL] [Abstract][Full Text] [Related]
33. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
Koga H; Naito S
Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
[No Abstract] [Full Text] [Related]
34. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
35. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
36. [A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate].
Suzuki Y; Aikawa K; Oishi Y; Yamazaki H; Onishi T; Suzuki M; Kobari T; Endo K; Yanada S; Kato N; Yoshino Y; Wada T; Ueda M; Takasaka S; Akazawa K
Nihon Hinyokika Gakkai Zasshi; 1998 Dec; 89(12):961-6. PubMed ID: 9990228
[TBL] [Abstract][Full Text] [Related]
37. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions.
Morgan G; Cooley C
Eur J Oncol Nurs; 2005 Dec; 9(4):334-40. PubMed ID: 16298160
[TBL] [Abstract][Full Text] [Related]
38. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
39. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
[TBL] [Abstract][Full Text] [Related]
40. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
